Nurix Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Nurix Therapeutics
NRIX Stock  USD 18.15  1.26  6.49%   
Nurix Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Nurix Therapeutics' valuation are provided below:
Gross Profit
-217.4 M
Profit Margin
(2.92)
Market Capitalization
2 B
Enterprise Value Revenue
18.2625
Revenue
83.7 M
We have found one hundred twenty available fundamental ratios for Nurix Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Nurix Therapeutics last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 1.4 B in 2026. Enterprise Value is likely to rise to about 1.3 B in 2026

Nurix Therapeutics Total Revenue

44.99 Million

Check Nurix Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nurix Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 326 K, Net Interest Income of 23.8 M or Interest Income of 23.8 M, as well as many indicators such as Price To Sales Ratio of 24.85, Dividend Yield of 0.0 or PTB Ratio of 2.66. Nurix financial statements analysis is a perfect complement when working with Nurix Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Nurix Stock
Check out the analysis of Nurix Therapeutics Correlation against competitors.
For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.

Nurix Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets808.2 M769.7 M292.3 M
Slightly volatile
Other Current Liabilities44.4 M42.3 M15.3 M
Slightly volatile
Total Current Liabilities64.9 M110.2 M53.8 M
Slightly volatile
Other Liabilities42.9 M41.4 M23.3 M
Slightly volatile
Property Plant And Equipment Net55.4 M52.8 M20.5 M
Slightly volatile
Current Deferred Revenue37.1 M44.1 M32.6 M
Slightly volatile
Accounts Payable13.9 M13.2 M4.9 M
Slightly volatile
Cash76.9 M126.5 M57.8 M
Slightly volatile
Non Current Assets Total75.6 M57.4 M41 M
Slightly volatile
Non Currrent Assets Other2.8 M4.7 M1.8 M
Slightly volatile
Other Assets5.4 M5.7 M7.5 M
Pretty Stable
Cash And Short Term Investments736.1 M701 M245.9 M
Slightly volatile
Common Stock Total Equity30.4 K54 K22.6 K
Slightly volatile
Common Stock Shares Outstanding44.6 M77.2 M34.4 M
Slightly volatile
Short Term Investments603.3 M574.5 M184.8 M
Slightly volatile
Liabilities And Stockholders Equity808.2 M769.7 M292.3 M
Slightly volatile
Non Current Liabilities Total48.2 M41.8 M53.2 M
Very volatile
Capital Surpluse856.4 M815.6 M322.6 M
Slightly volatile
Other Current Assets6.7 M9.5 M4.6 M
Slightly volatile
Total Liabilities116.1 M163.7 M82.3 M
Slightly volatile
Property Plant And Equipment Gross97.1 M92.5 M30.9 M
Slightly volatile
Total Current Assets747.9 M712.3 M252.2 M
Slightly volatile
Capital Stock91.8 K87.4 K31.7 K
Slightly volatile
Non Current Liabilities Other25.2 M48.8 M19.1 M
Slightly volatile
Net Working Capital632.2 M602.1 M195.4 M
Slightly volatile
Short Term Debt6.3 M9.2 M4.9 M
Slightly volatile
Common Stock91.8 K87.4 K31.7 K
Slightly volatile
Property Plant Equipment12.6 M19.7 M10.1 M
Slightly volatile
Net Receivables1.3 M1.4 M7.5 M
Slightly volatile
Short and Long Term Debt Total23.1 M32.5 M17.5 M
Slightly volatile
Deferred Long Term Liabilities400 K450 K491.2 K
Slightly volatile

Nurix Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income23.8 M22.7 M6.5 M
Slightly volatile
Interest Income23.8 M22.7 M6.5 M
Slightly volatile
Depreciation And Amortization6.1 M9.2 M4.9 M
Slightly volatile
Interest Expense17.3 M16.5 M6.4 M
Slightly volatile
Selling General Administrative29.8 M52.8 M21.4 M
Slightly volatile
Total Revenue45 M62.7 M41.8 M
Slightly volatile
Other Operating Expenses165.5 M307.7 M125 M
Slightly volatile
Research Development135.7 M254.9 M103.5 M
Slightly volatile
Cost Of Revenue267.6 M254.9 M94.6 M
Slightly volatile
Total Operating Expenses87.5 M52.8 M46.5 M
Slightly volatile
Reconciled Depreciation19.8 M18.9 M7.7 M
Slightly volatile
Total Other Income Expense Net23.8 M22.7 M6.5 M
Slightly volatile
Non Operating Income Net Other2 M4 M1.9 M
Slightly volatile
Selling And Marketing Expenses4.9 M5.5 M6 M
Slightly volatile

Nurix Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation41 M39 M13.7 M
Slightly volatile
Begin Period Cash Flow62.7 M63.9 M41.1 M
Slightly volatile
Other Cashflows From Financing Activities7.8 M8.2 M15.3 M
Pretty Stable
Depreciation19.8 M18.9 M7.7 M
Slightly volatile
Capital Expenditures6.8 M10.7 M4.8 M
Slightly volatile
Total Cash From Financing Activities586.4 M558.5 M160.8 M
Slightly volatile
End Period Cash Flow77.5 M127.5 M58.2 M
Slightly volatile
Change To Netincome34.2 M32.6 M12 M
Slightly volatile
Change To Inventory7.2 M6.1 M9.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio24.8531.2917.5714
Slightly volatile
Days Sales Outstanding10.9711.54145
Slightly volatile
Stock Based Compensation To Revenue0.30.560.2442
Slightly volatile
Capex To Depreciation1.030.650.7381
Slightly volatile
EV To Sales16.4823.1415.4103
Slightly volatile
Payables Turnover28.5622.227.6714
Slightly volatile
Sales General And Administrative To Revenue0.540.760.4813
Slightly volatile
Research And Ddevelopement To Revenue2.463.662.3074
Slightly volatile
Capex To Revenue0.130.150.1109
Slightly volatile
Cash Per Share5.68.175.2227
Slightly volatile
Days Payables Outstanding12.0617.0213.84
Slightly volatile
Net Debt To EBITDA0.440.462.1594
Slightly volatile
Current Ratio3.375.823.1623
Slightly volatile
Receivables Turnover27.8632.7316.7749
Slightly volatile
Debt To Equity0.05680.04830.0484
Slightly volatile
Capex Per Share0.130.120.1288
Slightly volatile
Revenue Per Share1.250.931.6029
Slightly volatile
Interest Debt Per Share0.30.380.3339
Slightly volatile
Debt To Assets0.03690.03810.0338
Slightly volatile
Operating Cycle10.9711.54144
Slightly volatile
Days Of Payables Outstanding12.0617.0213.84
Slightly volatile
Ebt Per Ebit1.051.040.946
Slightly volatile
Total Debt To Capitalization0.05160.04590.0455
Slightly volatile
Debt Equity Ratio0.05680.04830.0484
Slightly volatile
Quick Ratio3.375.823.1632
Slightly volatile
Net Income Per E B T1.051.151.0206
Pretty Stable
Cash Ratio1.51.321.1143
Slightly volatile
Days Of Sales Outstanding10.9711.54145
Slightly volatile
Fixed Asset Turnover1.31.375.1526
Slightly volatile
Debt Ratio0.03690.03810.0338
Slightly volatile
Price Sales Ratio24.8531.2917.5714
Slightly volatile
Asset Turnover0.0890.09370.4746
Slightly volatile

Nurix Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.4 B1.3 B690.5 M
Slightly volatile
Enterprise Value1.3 B1.3 B642.4 M
Slightly volatile

Nurix Fundamental Market Drivers

Nurix Upcoming Events

8th of February 2024
Upcoming Quarterly Report
View
11th of April 2024
Next Financial Report
View
30th of November 2023
Next Fiscal Quarter End
View
8th of February 2024
Next Fiscal Year End
View
31st of August 2023
Last Quarter Report
View
30th of November 2022
Last Financial Announcement
View

About Nurix Therapeutics Financial Statements

Nurix Therapeutics investors use historical fundamental indicators, such as Nurix Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Nurix Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue44.1 M37.1 M
Total Revenue62.7 M45 M
Cost Of Revenue254.9 M267.6 M
Stock Based Compensation To Revenue 0.56  0.30 
Sales General And Administrative To Revenue 0.76  0.54 
Research And Ddevelopement To Revenue 3.66  2.46 
Capex To Revenue 0.15  0.13 
Revenue Per Share 0.93  1.25 
Ebit Per Revenue(4.49)(4.72)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
HITIHigh Tide
HITIHigh Tide
BACBank of America

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY